Cancer Immunol Res. 2026 Jan 13:OF1-OF2. doi: 10.1158/2326-6066.CIR-25-1344. Online ahead of print.

ABSTRACT

Adoptive T-cell therapies have shown limited efficacy against solid tumors, so new approaches are required. In this issue, Chantzoura and colleagues describe MiNK-215, a novel allogeneic fibroblast activation protein-targeting chimeric antigen receptor invariant NK T-cell therapy engineered to secrete IL15. They show that it can remodel the tumor microenvironment and enhance antitumor immunity by depleting fibroblast activation protein-positive cancer-associated fibroblasts and activating multiple immune cell types. In mouse lung tumor and human organoid models, MiNK-215 promotes durable, antigen-specific T-cell responses and overcomes resistance to immunotherapy without causing off-target toxicity. See related article by Chantzoura et al., p. XX .

PMID:41528110 | DOI:10.1158/2326-6066.CIR-25-1344